Phase 1 dose-finding study of topical neostigmine ophthalmic solution for alleviating myasthenic ptosis Authors: Chuthamas Ongprakobkul, Supanut Apinyawasisuk, Supharat Jariyakosol, Pajaree Chariyavilaskul, Kornvalee Meesilpavikkai, Yuda Chongpison Published: 2026 ABSTRACT The study aimed to investigate the safety, optimal biologic dose, and preliminary efficacy of topical neostigmine ophthalmic solution (TNOS) in myasthenia gravis (MG) patients with ptosis. A dose-escalation study comprising cohorts of three patients in each step was performed. The first cohort received 1.5 mg/mL TNOS and was evaluated for safety and efficacy. Then, the subsequent cohorts received the selected dose of TNOS according to the safety and efficacy protocols to determine the optimal biologic dose. Vital signs, visual acuity, intraocular pressure, pupillary size, slit-lamp examinations, and abnormal ocular symptoms were recorded as safety measures. Vertical palpebral fissure and self-reported alleviation of ptosis were investigated as efficacy measures. No systemic or ocular adverse effects were observed in any participant. Vertical palpebral fissure increased by more than 2 mm in 83.3% and 33.3% of patients receiving 1.5 and 1.0 mg/mL TNOS, respectively. The 1.5 mg/mL TNOS significantly increased vertical palpebral fissure from baseline (maximal mean difference 3.30 mm; 95% confidence interval 2.32 to 4.27; p < 0.001). All participants in the 1.5 mg/mL group and 33.3% in the 1.0 mg/mL group reported ptosis alleviation. The 1.5 mg/mL TNOS was considered the optimal biologic dose for alleviating myasthenic ptosis without adverse events.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-51288-2. Introduction Myasthenia gravis (MG) is an autoimmune disease typically caused by acetylcholine receptor antibodies (AChR-Ab), which results in muscle weakness. Ptosis and diplopia are common initial presentations, and some patients have isolated ocular MG without generalized weakness1. Isolated myasthenic ptosis could not be easily distinguished from other causes of acquired blepharoptosis. Although the most common cause of acquired blepharoptosis is aponeurotic ptosis, a life-threatening condition, i.e., neurogenic ptosis, must be excluded. While ptosis from third cranial nerve palsy and Horner’s syndrome are usually combined with other clinical clues, such as ocular dysmotility or pupillary abnormalities that present in a specific clinical pattern, the diagnosis of MG is more complex because the pattern of muscle involvement is more unpredictable2. Clinical signs may not be evident due to fluctuations in nature, and serum AChR-Ab is positive in only 50% of ocular MG patients. Single-fiber electromyography (SF-EMG), the most sensitive test, is not widely available and requires expertise from medical providers and patient cooperation3–5. Currently, acetylcholinesterase inhibitors (AChEIs) for alleviating ptosis and ocular dysmotility in MG patients are available in oral and parenteral forms. A widening of the palpebral fissure after the injection of edrophonium or neostigmine supports MG diagnosis with good sensitivity and specificity of more than 90%. However, the utilization of these medications is limited because the administration procedures are complicated, and the drugs potentially cause life-threatening adverse events, including bronchospasm, cardiac arrhythmia, or even cardiac arrest6–8. While the mainstay of symptomatic MG treatment is oral pyridostigmine, it commonly causes systemic side effects, e.g., gastrointestinal distress and muscle twitching, which could affect patient compliance9. Despite frequent ocular symptoms, there is currently no available ophthalmic drop that directly alleviates myasthenic ptosis, which could be locally applied as a diagnostic tool or symptomatic treatment with fewer systemic side effects. Thus, the authors aimed to develop a topical neostigmine ophthalmic solution (TNOS) as a novel, safe, and simple drug formulation for alleviating ptosis in MG patients. The primary objective of this study is to evaluate the safety of TNOS in MG patients. The secondary objectives are to investigate the optimal biologic dose and the preliminary efficacy of TNOS in MG patients with ptosis. Methods Study design and ethical considerations A phase 1 dose-finding study was conducted in accordance with the tenets of the Declaration of Helsinki. The Institutional Review Board of the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand has prospectively approved the protocol (COA No. 1050/2023). Written informed consent for research participation and publication of information/image was obtained from all participants before enrollment. This clinical trial was registered with the Australian New Zealand Clinical Trials Registry (registration number ACTRN12624000545561; date of registration 30th April 2024). Preparation of topical neostigmine ophthalmic solution and sterility testing Commercially available parenteral neostigmine methyl sulfate solution (2.5 mg/mL) (Neostigmine GPO®, Government Pharmaceutical Organization, Bangkok, Thailand) was diluted with normal saline solution (NSS) to the prespecified concentrations under sterile conditions by a well-trained ophthalmologist. TNOS preparation was performed on the day of the experiment, and the remaining drug in the ampule was discarded. The sterility of TNOS preparation was confirmed by microbial culture using blood agar (Biomedia®, Nontaburi, Thailand), chocolate agar (Biomedia®, Nontaburi, Thailand), and Sabouraud dextrose agar (HiMedia®, Maharashtra, India). Participants We included patients aged 18 years or older who presented with ptosis and were diagnosed with MG by neuro-ophthalmologists or neurologists at the King Chulalongkorn Memorial Hospital, Bangkok, Thailand. The diagnosis was established when the patients had a high clinical suspicion of MG and met at least one of the following criteria, i.e., positive serum AChR-Ab, decremental pattern on repetitive nerve stimulation (RNS), positive SF-EMG, response to edrophonium test or neostigmine test, or unequivocal response to AChEIs and/or corticosteroid. The exclusion criteria were patients with generalized MG currently receiving medications, ocular MG currently receiving immunosuppressants, aponeurotic ptosis, mechanical ptosis, traumatic ptosis, other diseases of myogenic or neurogenic ptosis, ophthalmic diseases requiring ophthalmic drops other than lubricants, previous eyelid surgery or trauma, abnormal eyelid movement that interfere with the evaluation e.g., eyelid myokymia, facial tics, blepharospasm or facial spasm, neostigmine allergy, or contraindication to neostigmine. Participants receiving oral pyridostigmine at recruitment were requested to discontinue the medication at least 24 h before TNOS instillation and would restart their medication after a 24-hour post-instillation assessment. Baseline characteristics, including age, sex, duration of ptosis, type of MG (ocular MG or generalized MG), presenting symptoms, history of treatment, past medical illness, AChR-Ab status, and results of SF-EMG or RNS (if available), were recorded. Administration of topical neostigmine ophthalmic solution and dose rationale All experiments started at 9 AM to avoid the diurnal fluctuation of symptoms. A 50-µL TNOS was applied in the ptotic eye or the eye with more severe ptosis in patients with bilateral ptosis in a sitting position with a backward head tilt. The dose escalation method was based on the 3 + 3 design, consisting of a cohort of three patients in each step. The four designated dose levels included 0.5 mg/mL (50 µL), 1.0 mg/mL (50 µL), 1.5 mg/mL (50 µL), and 2.5 mg/mL (50 µL) (Fig. 1a). A starting dose for the first cohort was a single dose of 1.5 mg/mL (50 µL) TNOS based on the pharmacologically active dose, which is the “safe” lowest dose with “intended pharmacological activity”, derived from our preclinical animal study10. Regarding the animal study, TNOS was defined as “safe” when it caused no more than grade 1 ocular lesions according to the Organization for Economic Co-operation and Development (OECD) guidelines11 and no systemic adverse effects. The “intended pharmacological activity” was defined as the smaller mean pupillary size of the TNOS group than the control, more than 2 mm at any observed time point10. Fig. 1(a) Dose rationale and designated dose levels. The starting dose of 1.5 mg/mL topical neostigmine ophthalmic solution in the present study was derived from the previous animal study. (b) Safety and (c) efficacy protocols for dose selection and stopping rules. DLT, dose-limiting toxicity. (a) Dose rationale and designated dose levels. The starting dose of 1.5 mg/mL topical neostigmine ophthalmic solution in the present study was derived from the previous animal study. (b) Safety and (c) efficacy protocols for dose selection and stopping rules. DLT, dose-limiting toxicity. After safety and efficacy assessments, the subsequent cohort of other participants would receive the escalated, de-escalated, or same repeated dose according to the safety (Fig. 1b) and efficacy protocols (Fig. 1c) mentioned in the next section. The dose would be escalated, de-escalated, or repeated to determine the optimal biologic dose, which is the lowest dose providing efficacy and safety. Safety protocol Dose-limiting toxicity (DLT) is an unacceptable toxic effect presumably related to the drug that limits further dose escalation12. The DLT in this study was defined as adverse events more than grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.013. If none of the preceding cohort experienced the DLT, the dose level would be defined as “safe” and the subsequent cohort could receive the escalated dose. If one of the first three participants experienced the DLT, another cohort would receive the same repeated dose. If at least two of three or two of six participants experienced the DLT, the dose level would be defined as “unsafe” and the subsequent cohort would receive a de-escalated dose (Fig. 1b). Efficacy protocol Efficacy was defined as the maximal degree of vertical palpebral fissure widening from baseline greater than 2 mm during the observed period after TNOS instillation. If none or only one participant of the preceding cohort met the efficacy definition, the dose level would be defined as “inefficacious” and the subsequent cohort would receive the escalated dose. If at least two of the first three participants met the efficacy definition, another cohort would receive the same repeated dose. If at least five of six participants met the efficacy definition, the dose level would be defined as “efficacious” and the subsequent cohort would receive a de-escalated dose to determine the lowest dose providing efficacy (Fig. 1c). Safety assessment Systemic and ocular assessments were performed to evaluate safety. Vital signs (i.e., pulse rate, blood pressure, and respiratory rate), intraocular pressure, and pupillary size were measured at baseline, 15, 30, 60, 90, 120, 180 min, 24 h, and 7 days after instillation. Pupillary sizes were photographed with a calibration marker over time in the same room and under constant lighting condition. The camera model was Sony® α6000 (f/22, shutter speed 1/125, ISO 100) with the Sigma 70 mm f/2.8 DG Macro lens (Sony Corp., Bangkok, Thailand) and digital ring flash (Metz Consumer Electronics GmbH, Zirndorf, Germany). The pupillary sizes were measured in millimeters by ImageJ (US National Institutes of Health, Bethesda, Maryland, USA). Visual acuity (VA) and complete slit-lamp examination with fluorescein staining, including eyelid, conjunctiva, cornea, anterior chamber, and lens, were evaluated at baseline, 1 h, 24 h, and 7 days after instillation. A dilated fundus examination was performed at 7 days after instillation (Fig. 2). Participants were interviewed for symptoms of dimmed vision, blurred vision, eye irritation, eye itching, tearing, red eye, and eye pain. An adverse event was defined as any unfavorable and unintended signs, symptoms, or diseases temporally associated with a medical treatment that may or may not be considered related to the medical treatment. The adverse events were graded according to CTCAE Version 5.013. Fig. 2Outcome measurements at each time point after instillation of topical neostigmine ophthalmic solution. TNOS, topical neostigmine ophthalmic solution. Outcome measurements at each time point after instillation of topical neostigmine ophthalmic solution. TNOS, topical neostigmine ophthalmic solution. Efficacy assessment Ptosis was evaluated as a vertical palpebral fissure height, which is the distance at the widest point between the lower and upper eyelids. To evaluate efficacy, the vertical palpebral fissures were photographed with a calibration marker and measured in millimeters by ImageJ at baseline, 15, 30, 60, 90, 120, 180 min, and 24 h after instillation (Fig. 2). Participants were interviewed about changes in the ptosis symptom after the TNOS application. All assessments were performed by a single neuro-ophthalmologist who was blinded to TNOS applications. Statistical analysis The number of participants was based on a 3 + 3 dose escalation design12. A formal sample size calculation was not performed because this study was a dose escalation design. Baseline characteristics were described using median (first quartile, third quartile; Q1, Q3) for continuous data and frequency with percentages for categorical data. To evaluate safety, ocular abnormalities and adverse events would be presented as frequencies with percentages. The IOP and pupillary size were calculated as mean ± standard deviation (SD). To evaluate the IOP and pupillary size over time, linear mixed models with baseline values of IOP or pupillary size, respectively, as a covariate were used. Scheffé’s method was used for multiple comparisons. To evaluate efficacy, vertical palpebral fissure height was described as observed mean ± SD. A linear mixed model with baseline vertical palpebral fissure height as a covariate was used to evaluate vertical palpebral fissure height over time. Scheffé’s method was used for multiple comparisons. Proportions of participants with observed/reported ptosis alleviation in each dose group were demonstrated as frequencies with percentages and 95% confidence interval (95% CI) and were compared between dose groups with Fisher’s exact test. A p-value of less than 0.05 was considered statistically significant. All analyses were conducted using Stata version 19.5 software (StataCorp, College Station, Texas, USA). Results Sterility testing No microorganism was detected in TNOS samples throughout the incubation period. Baseline characteristics Twelve participants were included in the study and received 1.5 mg/mL (n = 6) or 1.0 mg/mL (n = 6) of TNOS. There were seven females and five males, with an overall median age of 61.5 (46.3, 67.8) years. The median duration from the onset of ptosis to the TNOS instillation was 23.5 (2.5, 93.5) months. Demographic and clinical characteristics are described in Table 1 and Supplementary Table S1 online. Table 1Demographic data and baseline clinical characteristics of 1.5 mg/mL and 1.0 mg/mL TNOS groups.Variables1.5 mg/mL TNOS (n = 6), N (%)1.0 mg/mL TNOS (n = 6), N (%) Sex Female4 (66.7)3 (50.0)Male2 (33.3)3 (50.0) Age (years), median (Q1, Q3) 62.5 (54.3, 67.3)59.5 (29.8, 68.0) Duration of ptosis (months), median (Q1, Q3) 50.0 (1.8, 165.8)4.5 (3.3, 58.5) Type of MG Ocular MG5 (83.3)6 (100.0)Generalized MG1 (16.7)0 (0.0) Presenting symptoms Ptosis6 (100.0)6 (100.0)Diplopia4 (66.7)0 (0.0)OOM weakness1 (16.7)1 (16.7)Limb weakness1 (16.7)0 (0.0) AChR-Ab status Positive4 (66.7)6 (100.0)Negative1 (16.7)0 (0.0)Not done1 (16.7)0 (0.0) Electrophysiologic study Positive RNS2 (33.3)0 (0.0)Not done4 (66.7)6 (100.0) Current treatment Oral pyridostigmine5 (83.3)4 (66.7)None1 (16.7)2 (33.3) Past medical illness Hypertension3 (50.0)2 (33.3)Hyperlipidemia2 (33.3)1 (16.7)Diabetes mellitus1 (16.7)2 (33.3)Cancer2 (33.3)1 (16.7)Coronary artery disease1 (16.7)0 (0.0)Asthma0 (0.0)1 (16.7)None1 (16.7)2 (33.3)TNOS = topical neostigmine ophthalmic solution; Q1 = first quartile; Q3 = third quartile; MG = myasthenia gravis; OOM = orbicularis oculi muscle; AChR-Ab = acetylcholine receptor antibodies; RNS = repetitive nerve stimulation. Table 1Demographic data and baseline clinical characteristics of 1.5 mg/mL and 1.0 mg/mL TNOS groups.Variables1.5 mg/mL TNOS (n = 6), N (%)1.0 mg/mL TNOS (n = 6), N (%) Sex Female4 (66.7)3 (50.0)Male2 (33.3)3 (50.0) Age (years), median (Q1, Q3) 62.5 (54.3, 67.3)59.5 (29.8, 68.0) Duration of ptosis (months), median (Q1, Q3) 50.0 (1.8, 165.8)4.5 (3.3, 58.5) Type of MG Ocular MG5 (83.3)6 (100.0)Generalized MG1 (16.7)0 (0.0) Presenting symptoms Ptosis6 (100.0)6 (100.0)Diplopia4 (66.7)0 (0.0)OOM weakness1 (16.7)1 (16.7)Limb weakness1 (16.7)0 (0.0) AChR-Ab status Positive4 (66.7)6 (100.0)Negative1 (16.7)0 (0.0)Not done1 (16.7)0 (0.0) Electrophysiologic study Positive RNS2 (33.3)0 (0.0)Not done4 (66.7)6 (100.0) Current treatment Oral pyridostigmine5 (83.3)4 (66.7)None1 (16.7)2 (33.3) Past medical illness Hypertension3 (50.0)2 (33.3)Hyperlipidemia2 (33.3)1 (16.7)Diabetes mellitus1 (16.7)2 (33.3)Cancer2 (33.3)1 (16.7)Coronary artery disease1 (16.7)0 (0.0)Asthma0 (0.0)1 (16.7)None1 (16.7)2 (33.3)TNOS = topical neostigmine ophthalmic solution; Q1 = first quartile; Q3 = third quartile; MG = myasthenia gravis; OOM = orbicularis oculi muscle; AChR-Ab = acetylcholine receptor antibodies; RNS = repetitive nerve stimulation. Demographic data and baseline clinical characteristics of 1.5 mg/mL and 1.0 mg/mL TNOS groups. TNOS = topical neostigmine ophthalmic solution; Q1 = first quartile; Q3 = third quartile; MG = myasthenia gravis; OOM = orbicularis oculi muscle; AChR-Ab = acetylcholine receptor antibodies; RNS = repetitive nerve stimulation. Dose selection The first cohort received 1.5 mg/mL TNOS. Two of the three participants met the efficacy criteria, and none of them experienced the DLT. Thus, the second cohort received the same dose, and all of them met the efficacy without DLT. The 1.5 mg/mL TNOS was efficacious and safe; thus, TNOS was de-escalated to 1.0 mg/mL in the subsequent cohort to identify the lowest efficacious dose. Two of three participants in the third cohort met the efficacy, and none experienced the DLT. Accordingly, the next cohort received the same dose, and none of them met the efficacy or DLT. The dose of 1.0 mg/mL was safe but inefficacious; thus, the lowest efficacious dose with safety was 1.5 mg/mL (Fig. 3). Fig. 3Dose selection of topical neostigmine ophthalmic solution and outcomes regarding safety and efficacy of participants in each cohort. DLT, dose-limiting toxicity. Dose selection of topical neostigmine ophthalmic solution and outcomes regarding safety and efficacy of participants in each cohort. DLT, dose-limiting toxicity. Safety All participants had no systemic or ocular adverse effects. Vital signs and VA were stable in all participants. The mean IOP showed no significant change from the baseline along the observed period in either concentration (Fig. 4a). Mean pupillary sizes decreased over time after instillation and then returned to baseline at 24 h in both concentrations. The maximal degrees of pupillary constriction from baseline were – 0.87 mm (95% CI -1.42 to -0.32; p = 0.001) in the 1.5 mg/mL TNOS group and – 0.82 mm (95% CI -1.37 to -0.26; p = 0.002) in the 1.0 mg/mL TNOS group (Fig. 4b). No participants reported abnormal ocular symptoms. Fig. 4(a) Adjusted mean intraocular pressure and (b) adjusted mean pupillary size over time after instillation of 1.5 mg/mL and 1.0 mg/mL topical neostigmine ophthalmic solution. Adjusted mean was obtained from linear mixed models with baseline intraocular pressure or pupillary size, respectively, as a covariate. TNOS, topical neostigmine ophthalmic solution. (a) Adjusted mean intraocular pressure and (b) adjusted mean pupillary size over time after instillation of 1.5 mg/mL and 1.0 mg/mL topical neostigmine ophthalmic solution. Adjusted mean was obtained from linear mixed models with baseline intraocular pressure or pupillary size, respectively, as a covariate. TNOS, topical neostigmine ophthalmic solution. Effect of topical neostigmine ophthalmic solution on vertical palpebral fissure Vertical palpebral fissure height increased more than 2 mm in five of six patients (83.3%; 95% CI 35.9 to 99.6) receiving 1.5 mg/mL TNOS and two of six patients (33.3%; 95% CI 4.3 to 77.7) receiving 1.0 mg/mL TNOS (p = 0.242). The maximal mean difference of vertical palpebral fissure height after instillation compared to baseline were 3.30 mm at 60 min (95% CI 2.32 to 4.27; p < 0.001) in the 1.5 mg/mL TNOS group (Fig. 5a) and 1.25 mm at 180 min (95% CI 0.27 to 2.22; p = 0.008) in the 1.0 mg/mL TNOS group (Fig. 5b). A significant increase in vertical palpebral fissure height compared to baseline was observed at all time points after 1.5 mg/mL TNOS instillation, but only at 180 min after 1.0 mg/mL TNOS instillation (Table 2; Figs. 5 and 6). All participants (100.0%; 95% CI 54.1 to 100.0) in the 1.5 mg/mL TNOS group and two participants (33.3%; 95% CI 4.3 to 77.7) in the 1.0 mg/mL TNOS group reported alleviation of ptosis (p = 0.061). Fig. 5Adjusted mean difference with 95% confidence interval of vertical palpebral fissure height at each time point compared to baseline in the (a) 1.5 mg/mL and (b) 1.0 mg/mL groups. (c) Adjusted mean vertical palpebral fissure height over time after instillation of 1.5 mg/mL and 1.0 mg/mL topical neostigmine ophthalmic solution. Adjusted mean and adjusted mean difference were obtained from a linear mixed model with baseline vertical palpebral fissure height as a covariate. TNOS, topical neostigmine ophthalmic solution; MD, mean difference. Adjusted mean difference with 95% confidence interval of vertical palpebral fissure height at each time point compared to baseline in the (a) 1.5 mg/mL and (b) 1.0 mg/mL groups. (c) Adjusted mean vertical palpebral fissure height over time after instillation of 1.5 mg/mL and 1.0 mg/mL topical neostigmine ophthalmic solution. Adjusted mean and adjusted mean difference were obtained from a linear mixed model with baseline vertical palpebral fissure height as a covariate. TNOS, topical neostigmine ophthalmic solution; MD, mean difference. Table 2Mean and mean difference of vertical palpebral fissure height at each time point against baseline after 1.5 mg/mL and 1.0 mg/mL TNOS instillation.Time1.5 mg/mL TNOS (n = 6)1.0 mg/mL TNOS (n = 6)Observed mean ± SD (mm)Adjusted mean† (95% CI) (mm)Adjusted MD† (95% CI) (mm)Adjustedp-valueObserved mean ± SD (mm)Adjusted mean† (95% CI) (mm)Adjusted MD†(95% CI) (mm)Adjustedp-value0 min6.19 ± 1.456.88 (6.15 to 7.61)7.59 ± 2.346.90 (6.17 to 7.62)15 min8.05 ± 1.278.74 (8.01 to 9.47) 1.86 (0.89 to 2.84) < 0.001* 7.92 ± 3.217.23 (6.50 to 7.96)0.33 (-0.64 to 1.31)0.70730 min8.67 ± 1.149.36 (8.64 to 10.09) 2.49 (1.51 to 3.46) < 0.001* 8.22 ± 2.987.52 (6.80 to 8.25)0.63 (-0.35 to 1.60)0.28860 min9.49 ± 0.6010.18 (9.45 to 10.90) 3.30 (2.32 to 4.27) < 0.001* 7.93 ± 2.347.24 (6.51 to 7.97)0.35 (-0.63 to 1.32)0.68790 min8.88 ± 0.899.57 (8.84 to 10.30) 2.69 (1.72 to 3.66) < 0.001* 8.51 ± 2.877.82 (7.09 to 8.55)0.93 (-0.05 to 1.90)0.067120 min8.72 ± 0.919.41 (8.68 to 10.13) 2.53 (1.55 to 3.50) < 0.001* 8.51 ± 3.177.82 (7.09 to 8.54)0.92 (-0.05 to 1.89)0.069180 min8.30 ± 0.908.99 (8.26 to 9.71) 2.11 (1.13 to 3.08) < 0.001* 8.83 ± 2.928.14 (7.41 to 8.87) 1.25 (0.27 to 2.22) 0.008* 24 h7.73 ± 1.298.42 (7.69 to 9.15) 1.54 (0.57 to 2.52) 0.001* 7.44 ± 2.896.75 (6.02 to 7.48)-0.15 (-1.12 to 0.83)0.936TNOS = topical neostigmine ophthalmic solution; SD = standard deviation; MD = mean difference; 95% CI = 95% confidence interval.†Adjusted mean and adjusted mean difference were obtained from a linear mixed model with baseline vertical palpebral fissure height as a covariate.*Adjusted p-value < 0.05 (Scheffé’s method for multiple comparisons). Table 2Mean and mean difference of vertical palpebral fissure height at each time point against baseline after 1.5 mg/mL and 1.0 mg/mL TNOS instillation.Time1.5 mg/mL TNOS (n = 6)1.0 mg/mL TNOS (n = 6)Observed mean ± SD (mm)Adjusted mean† (95% CI) (mm)Adjusted MD† (95% CI) (mm)Adjustedp-valueObserved mean ± SD (mm)Adjusted mean† (95% CI) (mm)Adjusted MD†(95% CI) (mm)Adjustedp-value0 min6.19 ± 1.456.88 (6.15 to 7.61)7.59 ± 2.346.90 (6.17 to 7.62)15 min8.05 ± 1.278.74 (8.01 to 9.47) 1.86 (0.89 to 2.84) < 0.001* 7.92 ± 3.217.23 (6.50 to 7.96)0.33 (-0.64 to 1.31)0.70730 min8.67 ± 1.149.36 (8.64 to 10.09) 2.49 (1.51 to 3.46) < 0.001* 8.22 ± 2.987.52 (6.80 to 8.25)0.63 (-0.35 to 1.60)0.28860 min9.49 ± 0.6010.18 (9.45 to 10.90) 3.30 (2.32 to 4.27) < 0.001* 7.93 ± 2.347.24 (6.51 to 7.97)0.35 (-0.63 to 1.32)0.68790 min8.88 ± 0.899.57 (8.84 to 10.30) 2.69 (1.72 to 3.66) < 0.001* 8.51 ± 2.877.82 (7.09 to 8.55)0.93 (-0.05 to 1.90)0.067120 min8.72 ± 0.919.41 (8.68 to 10.13) 2.53 (1.55 to 3.50) < 0.001* 8.51 ± 3.177.82 (7.09 to 8.54)0.92 (-0.05 to 1.89)0.069180 min8.30 ± 0.908.99 (8.26 to 9.71) 2.11 (1.13 to 3.08) < 0.001* 8.83 ± 2.928.14 (7.41 to 8.87) 1.25 (0.27 to 2.22) 0.008* 24 h7.73 ± 1.298.42 (7.69 to 9.15) 1.54 (0.57 to 2.52) 0.001* 7.44 ± 2.896.75 (6.02 to 7.48)-0.15 (-1.12 to 0.83)0.936TNOS = topical neostigmine ophthalmic solution; SD = standard deviation; MD = mean difference; 95% CI = 95% confidence interval.†Adjusted mean and adjusted mean difference were obtained from a linear mixed model with baseline vertical palpebral fissure height as a covariate.*Adjusted p-value < 0.05 (Scheffé’s method for multiple comparisons). Mean and mean difference of vertical palpebral fissure height at each time point against baseline after 1.5 mg/mL and 1.0 mg/mL TNOS instillation. TNOS = topical neostigmine ophthalmic solution; SD = standard deviation; MD = mean difference; 95% CI = 95% confidence interval. †Adjusted mean and adjusted mean difference were obtained from a linear mixed model with baseline vertical palpebral fissure height as a covariate. *Adjusted p-value < 0.05 (Scheffé’s method for multiple comparisons). Fig. 6Vertical palpebral fissure height before (a, b) and 60 min after (c, d) instillation of 1.5 mg/mL topical neostigmine ophthalmic solution. Vertical palpebral fissure height before (a, b) and 60 min after (c, d) instillation of 1.5 mg/mL topical neostigmine ophthalmic solution. Discussion No adverse event related to TNOS application was found in both 1.5 and 1.0 mg/mL concentrations. However, 1.5 mg/mL TNOS met the efficacy criteria for ptosis alleviation and significantly increased vertical palpebral fissure height. Based on this study’s findings, the authors proposed that 1.5 mg/mL TNOS might be considered the optimal biologic dose for alleviating myasthenic ptosis. Regarding the safety profile, no ocular inflammation was observed in this study, in agreement with previous studies in rabbits and MG patients10,14. TNOS potentially causes pupillary constriction and ciliary spasm by muscarinic effect15. However, to our knowledge, the effects of topical neostigmine on pupillary size and IOP in humans have not been reported. Our study demonstrated that the mean pupillary size decreased over time and returned to baseline at 24 h, consistent with findings from previous studies in rabbit models10,14. However, the magnitude of pupillary constriction in this human study was not clinically significant, contrary to the substantial miosis observed in rabbit models after 1.5 and 2.5 mg/mL TNOS instillations10,14. Considering clinical relevance, no participants reported symptoms of miosis or ciliary spasm, e.g., dimmed vision, blurred vision, or eye pain. The possible mechanism of small miotic effect in our participants may be explained by the fact that all participants in this study had dark-colored irises. This hypothesis was supported by a previous study, which reported a greater miotic effect of 0.025% brimonidine tartrate eyedrop in light-colored iris than dark-colored iris16. The effect of TNOS on the change of pupillary size in light-colored iris should be further investigated. AChEIs could reduce IOP by increasing aqueous outflow or increase IOP by aggravating paradoxical angle closure in some clinical settings15,17,18. The present study demonstrated stable mean IOP over time after 1.5 and 1.0 mg/mL TNOS instillation. Although our previous animal study showed a statistically significant decrease in mean IOP after 1.0 and 2.5 mg/mL TNOS applications, the degree of change was clinically insignificant10. The dilated fundus examination did not show retinal breaks or retinal detachment, which are possible side effects of miotic agents19,20. Apart from ocular examinations, vital signs were monitored to detect cardiopulmonary adverse events potentially associated with systemic AChEIs6. Vital signs were stable during the 7-day observation period, implying that TNOS was minimally absorbed into systemic circulation. Given its limited systemic absorption and consequently lower risk of systemic cardiopulmonary effects, the authors proposed that TNOS could potentially serve as a diagnostic tool or alternative treatment with a more favorable safety profile than systemic AChEIs. Safety evaluations in our study were extended to 7 days to detect the possible delayed side effects. The 1.5 mg/mL TNOS caused a statistically significant increase in vertical palpebral fissure height. The height increased more than 2 mm compared to the baseline from 30 to 180 min, with a peak effect at 60 min. The finding was consistent with a previous study14 that reported an increase in palpebral fissure height of more than 2 mm at 30 min after eye instillation of 2.5 mg/mL neostigmine in six MG patients. However, a degree of increase and change over time was not reported, and the effect of other dosages of topical neostigmine has not been investigated14. The present study provided a more comprehensive assessment of safety and the detailed measurement of the palpebral fissure widening effect in various TNOS dosages. Based on our findings, the authors proposed the lower concentration of topical neostigmine as an optimal biologic dose for myasthenic ptosis. Since the ocular pharmacokinetics of the topical neostigmine have not been studied, the timing of outcome assessment in this study was extrapolated from the pharmacokinetics of the intramuscular neostigmine. This approach was based on findings from our previous animal study10, in which the estimated timing of action following topical ophthalmic neostigmine instillation was similar to that observed with intramuscular administration. In this study, the onset and duration of 1.5 mg/mL TNOS on palpebral fissure widening are also comparable with conventional diagnostic tests using intramuscular neostigmine, in which the effect is typically observed at 30 to 45 min after injection and lasts for several hours21. It could be speculated that TNOS might be used as a diagnostic tool, instead of the conventional intramuscular neostigmine test, with a safer profile. However, this speculation requires further studies to evaluate the sensitivity and specificity of TNOS in diagnosing MG. As the maximal effect of ptosis alleviation was observed at 60 min in this study, the authors proposed defining the prespecified efficacy estimand for a positive test in future diagnostic studies as vertical palpebral fissure widening greater than 2 mm at 60 min after TNOS instillation. Apart from the diagnostic aspect, the authors proposed that the palpebral fissure widening effect of 1.5 mg/mL TNOS observed in our participants supported the possibility of its application as an alternative treatment for isolated ocular MG or adjuvant local therapy for generalized MG patients who receive full systemic medication but still manifest ptosis. However, this speculation requires further study evaluating the effect of eyelid elevation by measuring the margin-reflex distance 1 and patient’s vision-related quality of life improvement after receiving TNOS. The effect was less than 2 mm in only one participant with a palpebral fissure height of 8.64 mm before TNOS instillation, which was the maximum height among all participants. There were some possible explanations for this interesting finding. Firstly, the patient’s disease status might be inactive at the time of the study. Thus, the increasing acetylcholine level at the synaptic junction caused by TNOS might not be significant enough to enhance the nicotinic effect at the post-synaptic acetylcholine receptors that were well activated by the neurotransmitter. Secondly, in such a patient who had a wide palpebral fissure before an instillation, there might be a small residual height left that could be elevated by the effect of AChEIs to reach the patient’s maximal palpebral fissure height. However, these explanations require further investigation of the relationship between the pre-instillation palpebral fissure height and the degree of elevation produced by TNOS. Moreover, the disease activity at the time of instillation should be evaluated by various methods, such as serum AChR-Ab level and other MG activity scores. Considering other topical ophthalmic solutions relieving acquired blepharoptosis, the United States Food and Drug Administration (USFDA) recently approved 0.1% oxymetazoline, which stimulates alpha-adrenergic receptors in the Müller muscle22. The effect of eyelid elevation by 0.1% oxymetazoline was minimal in previous studies in patients with non-myasthenic ptosis. The increase in upper eyelid height was greater in the treatment arm than the vehicle arm by only 0.47 mm at 6 h and by 0.67 mm at 2 h after instillation23. A possible mechanism underlying the smaller degree of upper eyelid elevation compared to TNOS is that the Müller muscle can elevate the upper eyelid only 1 to 2 mm. In contrast, TNOS acts on nicotinic acetylcholine receptors in the levator palpebrae superioris muscle, which is a major eyelid retractor that contributes to eyelid elevation up to 15 mm24. The clinical benefits of the marginal degree of improvement by oxymetazoline may be limited to patients with minimal ptosis who have cosmetic concerns or to patients not suitable for surgical eyelid correction due to ocular or systemic comorbidities22. Besides, it can cause side effects, including punctate keratitis, conjunctival hyperemia, and blurred vision23. The application of 0.1% oxymetazoline in myasthenic ptosis remains inconclusive. The drug only stimulates adrenergic activity on the minor eyelid retractor and does not directly target a pathogenic muscle of MG. Although there have been two case reports about the use of 0.1% oxymetazoline in MG patients25,26 proposing that it could increase upper eyelid height, the effect on myasthenic ptosis requires further investigation. This phase 1 study utilized a 3 + 3 design as a primary safety framework to evaluate TNOS in MG patients. While acknowledging that this design often identifies doses below a true maximum tolerated dose, reaching a definitive toxicity-driven endpoint was practically unfeasible due to the concentration ceiling of the parenteral starting material. Consequently, the study identified the optimal biologic dose, defined by clinical alleviation in ptosis, as a more appropriate target. This conservative approach established a recommended phase 2 dose that balances biological activity with formulation constraints, aligning with modern regulatory preferences for dose optimization. The strengths of this study primarily involve the study design and the novelty of the research objectives. To the authors’ knowledge, this is the first dose-finding study of topical AChEIs in MG patients presenting with ptosis. The authors followed the standard dose-escalation design to provide patient safety and minimize the exposure of too many patients to subtherapeutic doses. The inclusion and exclusion criteria were well-established, and the participants discontinued current oral pyridostigmine before the experiment to avoid possible confounders. The dose rationale was based on a previous animal study10, and sterility of the TNOS preparation was confirmed before patient applications. Several parameters, which were not previously investigated, including IOP, pupillary size, VA, and fundus examination, were evaluated as safety measures. The effects of TNOS on vertical palpebral fissure height were demonstrated in quantitative data at frequent time points and a duration long enough to estimate the timing of action. Since this is a phase 1 dose-finding study, the first limitation is a relatively small sample size. Although the preliminary efficacy of TNOS on vertical palpebral fissure height was obtained from this study, the ability to observe significance in other outcomes was limited. Secondly, the outcomes of this study were observed in a single instillation of TNOS; the effects of multiple administrations and long-term safety profile should be investigated. Thirdly, this study provided the lowest efficacious dose rather than the maximum tolerated dose due to our expected clinical applications of TNOS and difficulty in reaching the maximum tolerated dose. This lowest efficacious dose has potential limitations in future diagnostic and therapeutic studies, as well as in clinical settings, because the lowest efficacious dose might give lower accuracy than the maximum tolerated dose when being used as a diagnostic tool and lower efficacy when being used as an alternative treatment for MG. In addition, although preliminary clinical efficacy and estimated timing of action were obtained from this study, the exact ocular pharmacodynamics and pharmacokinetics of TNOS remain unknown. Lastly, the efficacy demonstrated in this study was confined to an increase in vertical palpebral fissure height, without assessment of functional outcomes, adequate patient-reported measures, or ocular surface-specific tolerability. The authors acknowledge this limitation, particularly given that TNOS is used in clinical settings, and suggest that these parameters should be addressed in future studies. The development of TNOS as a diagnostic tool or therapeutic agent in patients with myasthenic ptosis might offer distinct benefits over systemic AChEIs, including reduced systemic side effects and greater simplicity in preparation and administration. The authors thus plan to conduct future studies addressing these issues. Parenteral neostigmine is a widely available drug commonly used in general anesthesia. Additionally, the price per dose of TNOS is relatively low compared to oral pyridostigmine, and the proposed dosage is approximately 20 to 60 times lower than that of intramuscular neostigmine6,21. The authors suggested that 1.5 mg/mL TNOS was the optimal concentration for a topical eyedrop formulation for alleviating ptosis in MG patients. The present study provided fundamental knowledge and enhanced the possibility of developing TNOS as a novel diagnostic tool or alternative therapeutic agent. However, further studies using 1.5 mg/mL TNOS in greater numbers of patients with ptosis should be conducted to investigate diagnostic and therapeutic performance. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1